Minsheng Group

Hangzhou Minsheng Pharmaceutical Holding Group is a long-established Chinese healthcare and pharmaceutical group whose roots trace back to 1926. The group operates across prescription drugs, APIs, health products, medical devices, medical services, and animal health, and includes manufacturing subsidiaries such as Shaoxing Minsheng Pharmaceutical as well as the publicly listed nutrition and OTC arm Hangzhou Minsheng Healthcare. Its commercial portfolio spans hospital injectables, anti-infectives, ophthalmics, metabolic disease products, vitamins and minerals, and API manufacturing for domestic and export markets. Recent company disclosures also indicate an emerging innovative drug effort, including a Class 1 new drug that received IND clearance for moderate-to-severe active ulcerative colitis in 2025. Overall, Minsheng is best characterized as a diversified commercial pharma and healthcare group rather than a pure-play biotech.